Parent psychopathology and offspring mental disorders: results from the WHO World Mental Health Surveys
| Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
|---|---|
| Data(s) |
05/11/2013
05/11/2013
2012
|
| Resumo |
Background Associations between specific parent and offspring mental disorders are likely to have been overestimated in studies that have failed to control for parent comorbidity. Aims To examine the associations of parent with respondent disorders. Method Data come from the World Health Organization (WHO) World Mental Health Surveys (n = 51 507). Respondent disorders were assessed with the Composite International Diagnostic Interview and parent disorders with informant-based Family History Research Diagnostic Criteria interviews. Results Although virtually all parent disorders examined (major depressive, generalised anxiety, panic, substance and antisocial behaviour disorders and suicidality) were significantly associated with offspring disorders in multivariate analyses, little specificity was found. Comorbid parent disorders had significant sub-additive associations with offspring disorders. Population-attributable risk proportions for parent disorders were 12.4% across all offspring disorders, generally higher in high- and upper-middle-than low-/lower-middle-income countries, and consistently higher for behaviour (11.0-19.9%) than other (7.1-14.0%) disorders. Conclusions Parent psychopathology is a robust non-specific predictor associated with a substantial proportion of offspring disorders. Analysis Group Analysis Group BristolMyers Squibb Bristol-Myers Squibb Eli Lilly Company Eli Lilly Company EPIQ EPI-Q GlaxoSmithKline GlaxoSmithKline Johnson & Johnson Pharmaceuticals Johnson & Johnson Pharmaceuticals Ortho-McNeil Janssen Scientific Affairs OrthoMcNeil Janssen Scientific Affairs Pfizer Pfizer SanofiAventis Groupe Sanofi-Aventis Groupe Shire US Shire US United States National Institute of Mental Health [R01MH070884, R01MH093612] United States National Institute of Mental Health NIMH NIMH [HHSN271200700030C] John D. and Catherine T. MacArthur Foundation John D. and Catherine T. MacArthur Foundation Pfizer Foundation Pfizer Foundation US Public Health Service US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558] Fogarty International Center [FIRCA R03-TW006481] Fogarty International Center Pan American Health Organization (PAHO) Pan American Health Organization (PAHO) Eli Lilly & Company Foundation Eli Lilly & Company Foundation OrthoMcNeil Pharmaceutical Ortho-McNeil Pharmaceutical Shire Shire State of Sao Paulo Research Foundation (FAPESP) State of Sao Paulo Research Foundation (FAPESP) [03/00204-3] Ministry of Health Ministry of Health National Center for Public Health Protection National Center for Public Health Protection Shenzhen Bureau of Health Shenzhen Bureau of Health Shenzhen Bureau of Science, Technology, and Information Shenzhen Bureau of Science, Technology, and Information Ministry of Social Protection Ministry of Social Protection European Commission European Commission [QLG5-1999-01042, SANCO 20041231] Piedmont Region (Italy) Piedmont Region (Italy) Fondo de Investigacion Sanitaria, Institut de Salud Carlos III, Spain [FIS 00/0028] Fondo de Investigacion Sanitaria, Institut de Salud Carlos III, Spain Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE] Ministerio de Ciencia y Tecnologia, Spain Departament de Salut, Generalitat de Catalunya, Spain, Institut de Salud Carlos III Departament de Salut, Generalitat de Catalunya, Spain, Institut de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP] Government of India Government of India WHO WHO United Nations Development Group (UNDG) United Nations Development Group (UNDG) Japan Ministry of Health, Labour and Welfare Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013] Lebanese Ministry of Public Health Lebanese Ministry of Public Health WHO (Lebanon) WHO (Lebanon) National Institute of Health/Fogarty International Center National Institute of Health/Fogarty International Center [R03 TW006481-01] Janssen Cilag Janssen Cilag Eli Lilly Eli Lilly AstraZeneca AstraZeneca Hikma Pharm Hikma Pharm Novartis Novartis National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280] National Institute of Psychiatry Ramon de la Fuente National Council on Science and Technology National Council on Science and Technology [CONACyT-G30544-H] WHO (Geneva) WHO (Geneva) WHO (Nigeria) WHO (Nigeria) Federal Ministry of Health, Abuja, Nigeria Federal Ministry of Health, Abuja, Nigeria Health & Social Care Research & Development Division of the Public Health Agency Health & Social Care Research & Development Division of the Public Health Agency Champalimaud Foundation Champalimaud Foundation Gulbenkian Foundation Gulbenkian Foundation Foundation for Science and Technology (FCT) Foundation for Science and Technology (FCT) US National Institute of Mental Health [R01-MH059575, RO1-MH61905] US National Institute of Mental Health National Institute of Drug Abuse National Institute of Drug Abuse South African Department of Health South African Department of Health University of Michigan university of Michigan National Institute of Mental Health [U01-MH60220] National Institute of Mental Health Robert Wood Johnson Foundation Robert Wood Johnson Foundation [044708] |
| Identificador |
BRITISH JOURNAL OF PSYCHIATRY, LONDON, v. 200, n. 4, supl. 1, Part 2, pp. 290-299, APR, 2012 0007-1250 http://www.producao.usp.br/handle/BDPI/41042 10.1192/bjp.bp.111.101253 |
| Idioma(s) |
eng |
| Publicador |
ROYAL COLLEGE OF PSYCHIATRISTS LONDON |
| Relação |
BRITISH JOURNAL OF PSYCHIATRY |
| Direitos |
closedAccess Copyright ROYAL COLLEGE OF PSYCHIATRISTS |
| Palavras-Chave | #SUBSTANCE USE DISORDERS #PROSPECTIVE-LONGITUDINAL-COMMUNITY #NATIONAL COMORBIDITY SURVEY #ENVIRONMENTAL RISK-FACTORS #FAMILY-HISTORY METHOD #MAJOR DEPRESSION #ANXIETY DISORDERS #CHILDHOOD ADVERSITIES #PSYCHIATRIC-DISORDERS #PANIC DISORDER #PSYCHIATRY |
| Tipo |
article original article publishedVersion |
